One in Five Pharmacies Refuses to Dispense Buprenorphine for Addiction Treatment, Study Finds

Despite decades of evidence demonstrating that medication-assisted treatment saves lives, a new study reveals that one in five pharmacies across the United States refuses to dispense buprenorphine—a critical medication for treating opioid use disorder. The findings, published in Drug and Alcohol Dependence, expose persistent barriers that prevent individuals from accessing one of the most effective treatments for addiction available today.

Researchers contacted hundreds of pharmacies nationwide to determine whether they would fill prescriptions for buprenorphine, which is FDA-approved for treating opioid dependence and has been shown to reduce overdose mortality by more than 50 percent compared to no treatment. The results reveal a fragmented landscape where access to this life-saving medication depends heavily on geography and pharmacy ownership structure.

Geographic and Ownership Disparities

The study found significant variation in buprenorphine availability depending on both region and pharmacy type. Independent pharmacies demonstrated substantially higher refusal rates than chain pharmacies, suggesting that corporate policies at major retailers may provide some protection against the stigma that continues to surround addiction treatment medications.

Regional differences proved equally stark. Pharmacies located in southern states showed significantly higher likelihood of restricting buprenorphine access compared to other regions of the country. This geographic pattern raises troubling questions about equity in addiction treatment, as the South has been disproportionately affected by the opioid crisis and continues to experience high rates of overdose deaths.

The southern concentration of pharmacy refusals compounds existing barriers in a region where Medicaid expansion remains limited, rural healthcare infrastructure is often underdeveloped, and cultural attitudes toward addiction treatment can be less supportive than in other parts of the country. For individuals seeking medication-assisted treatment in these areas, pharmacy refusal can represent an insurmountable obstacle to recovery.

The Stigma Behind the Counter

Pharmacy-level barriers to buprenorphine access reflect deeper societal attitudes that continue to characterize addiction as a moral failing rather than a medical condition. Unlike other chronic diseases, substance use disorders carry a persistent stigma that influences healthcare delivery at every level—including the pharmacy counter where patients present prescriptions.

Some pharmacists and pharmacy owners express concerns about diversion, fearing that buprenorphine prescribed for addiction treatment might be sold or misused. While diversion is a legitimate concern that requires appropriate safeguards, the study suggests that blanket refusal policies go far beyond reasonable precautions. Buprenorphine's pharmacological properties—including its ceiling effect on respiratory depression and long half-life—actually make it less prone to dangerous misuse than full opioid agonists.

Other pharmacies cite logistical challenges, such as limited stocking of buprenorphine products or unfamiliarity with the specific formulations used for addiction treatment versus pain management. These operational barriers, while real, are solvable through education and policy changes that normalize addiction treatment within standard pharmacy practice.

Regulatory Context and Recent Reforms

The study arrives at a moment of significant regulatory change in addiction treatment policy. The Mainstreaming Addiction Treatment (MAT) Act, passed by Congress in December 2022, eliminated the X-waiver requirement that previously restricted which healthcare providers could prescribe buprenorphine for opioid use disorder. This change dramatically expanded the pool of potential prescribers, allowing any DEA-registered clinician to provide this treatment.

More recently, the SUPPORT for Patients and Communities Reauthorization Act of 2025 authorized accredited continuing education for pharmacists interested in prescribing buprenorphine, though states must first authorize such prescribing before training becomes available. These federal reforms recognize that expanding access to medication-assisted treatment requires addressing barriers at multiple points in the care continuum—from prescriber authorization to pharmacy dispensing.

However, the new research demonstrates that regulatory changes focused on prescribers alone are insufficient. Even as more physicians, nurse practitioners, and physician assistants gain authority to prescribe buprenorphine, pharmacy-level refusals can nullify these gains by preventing patients from actually obtaining their prescribed medication.

Patient Impact and Public Health Consequences

For individuals with opioid use disorder, pharmacy refusal is not merely an inconvenience—it can be a life-threatening barrier to care. Medication-assisted treatment works by stabilizing brain chemistry, reducing cravings, and blocking the euphoric effects of other opioids. Interruptions in treatment, whether due to inability to fill prescriptions or gaps between doses, increase vulnerability to relapse and overdose.

The study's findings help explain why treatment access remains limited despite expanded prescribing authority. Research consistently shows that only a fraction of individuals with opioid use disorder receive medication-assisted treatment, with estimates suggesting that fewer than 25 percent of those who could benefit from such treatment actually receive it. Pharmacy barriers represent one piece of this access puzzle, alongside workforce shortages, insurance limitations, and geographic maldistribution of providers.

The consequences extend beyond individual patients to community-level public health outcomes. Areas with limited buprenorphine access experience higher overdose death rates, greater healthcare utilization for complications of untreated addiction, and increased criminal justice involvement related to substance use. Pharmacy refusal policies, while appearing to affect only individual transactions, contribute to these broader population health disparities.

Policy Responses and Potential Solutions

Addressing pharmacy-level barriers to buprenorphine access will require multi-faceted policy approaches that combine education, regulation, and incentives. Some states have already begun implementing requirements that pharmacies stock and dispense addiction treatment medications, treating buprenorphine similarly to other essential medications that cannot be arbitrarily refused.

Professional pharmacy organizations can play a role by developing practice guidelines that normalize addiction treatment dispensing and by providing continuing education on the clinical management of opioid use disorder. Such education can address both the practical aspects of buprenorphine dispensing and the attitudinal factors that contribute to stigma-driven refusal.

Insurance and payment policies also matter. When buprenorphine reimbursement rates are inadequate or when prior authorization requirements create administrative burdens, pharmacies may have financial incentives to avoid stocking and dispensing these products. Aligning payment policies with public health goals can help ensure that pharmacies view addiction treatment medications as a standard part of their business rather than a problematic outlier.

The Path Forward

The study's revelation that 20 percent of pharmacies refuse buprenorphine dispensation represents both a challenge and an opportunity. The challenge lies in the persistence of barriers that limit access to evidence-based addiction treatment despite decades of research demonstrating its effectiveness. The opportunity emerges from the clarity provided by this data, which identifies specific points of intervention—particular regions and pharmacy types—where policy and practice changes could yield substantial improvements in treatment access.

As the nation continues grappling with an opioid crisis that has claimed hundreds of thousands of lives, ensuring that effective treatments reach those who need them remains an urgent priority. Pharmacy access represents a critical link in the treatment chain, one that cannot be overlooked in broader efforts to expand medication-assisted treatment. The study serves as a reminder that even the most effective medical interventions cannot save lives if structural barriers prevent patients from obtaining them.

For individuals and families affected by opioid use disorder, the findings validate experiences of frustration and delay that too often characterize the search for treatment. For policymakers and healthcare leaders, the research provides a roadmap for targeted interventions that could substantially improve access to one of the most powerful tools available for addressing the addiction crisis.